Evidence map›Paper›PMID 26503812›Full record

ArticleThe pharmacogenomics journal2016

Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.

E Rumiato, A Brunello, S Ahcene-Djaballah, L Borgato, M Gusella, D Menon, F Pasini, A Amadori, D Saggioro, V Zagonel

Open access · greenAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

E RumiatoImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.ORCID 0000-0002-1142-0006
A BrunelloMedical Oncology 1 Unit, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
S Ahcene-DjaballahMedical Oncology 1 Unit, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
L BorgatoHemato-Oncology Unit, Medical Science Department ULSS 13, Mirano, Venezia, Italy.
M GusellaDivision of Oncology, Rovigo General Hospital, ULSS 18, Rovigo, Italy.
D MenonDivision of Oncology, Rovigo General Hospital, ULSS 18, Rovigo, Italy.
F PasiniDivision of Oncology, Rovigo General Hospital, ULSS 18, Rovigo, Italy.
A AmadoriImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
D SaggioroImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
V ZagonelMedical Oncology 1 Unit, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Istituto Oncologico Veneto · ITOspedale Santa Maria della Misericordia di Rovigo · ITOspedale di Mirano · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

So far, no reliable predictive clinicopathological markers of response to aromatase inhibitors (AIs) have been identified, and little is known regarding the role played by host genetics. To identify constitutive predictive markers, an array-based association study was performed in a cohort of 55 elderly hormone-dependent breast cancer (BC) patients treated with third-generation AIs. The array used in this study interrogates variants in 225 drug metabolism and disposition genes with documented functional significance. Six variants emerged as associated with response to AIs: three located in ABCG1, UGT2A1, SLCO3A1 with a good response, two in SLCO3A1 and one in ABCC4 with a poor response. Variants in the AI target CYP19A1 resulted associated with a favourable response only as haplotype; haplotypes with increased response association were also detected for ABCG1 and SLCO3A1. These results highlight the relevance of host genetics in the response to AIs and represent a first step toward precision medicine for elderly BC patients.

Indexed as

Oligonucleotide Array Sequence AnalysisPharmacogenomic VariantsAgedAged, 80 and overAge FactorsAntineoplastic Agents, HormonalAromataseAromatase InhibitorsATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily G, Member 1Biomarkers, TumorBreast NeoplasmsFemaleGene Expression ProfilingGlucuronosyltransferaseHaplotypesABCC4 protein, humanABCG1 protein, humanAntineoplastic Agents, HormonalAromataseAromatase InhibitorsATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily G, Member 1Biomarkers, TumorCYP19A1 protein, humanGlucuronosyltransferaseOrganic Anion TransportersReceptors, EstrogenSLCO3A1 protein, humanUGT2A1 protein, human

Identifiers

PMID26503812
OpenAlexW1829876388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.